WO2017009754A1 - Forme posologique de film administrable par voie orale contenant du fingolimod - Google Patents

Forme posologique de film administrable par voie orale contenant du fingolimod Download PDF

Info

Publication number
WO2017009754A1
WO2017009754A1 PCT/IB2016/054102 IB2016054102W WO2017009754A1 WO 2017009754 A1 WO2017009754 A1 WO 2017009754A1 IB 2016054102 W IB2016054102 W IB 2016054102W WO 2017009754 A1 WO2017009754 A1 WO 2017009754A1
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
polymer
fingolimod
film
film dosage
Prior art date
Application number
PCT/IB2016/054102
Other languages
English (en)
Inventor
Venkatanarayana KURELLA
Sridhar RUDRAVARAPU
Chaturvedi AKSHAY KANT
Original Assignee
Shilpa Medicare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shilpa Medicare Limited filed Critical Shilpa Medicare Limited
Publication of WO2017009754A1 publication Critical patent/WO2017009754A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Definitions

  • the invention relates to orally administrable, disintegrating film dosage forms comprising fingolimod or pharmaceutically acceptable salts or solvates thereof and methods of orally administering the film dosage forms.
  • Fingolimod is a sphingosine 1 -phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
  • Fingolimod itself is a prodrug and gets phosphorylated to the active metabolite (S) - fingolimod phosphate ester by sphingosine kinases in liver cells.
  • Fingolimod may form stable acid addition salts, of which fingolimod hydrochloride is the most common one.
  • Chemically fingolimod hydrochloride is 2-amino-2-[2-(4-octylphenyl)ethyl]propan-l,3-diol hydrochloride and chemically represented as
  • Fingolimod hydrochloride dosage form marketed in US is a hard-shell capsule filled with a powder comprising 0.56 mg of Fingolimod hydrochloride (corresponding to 0.5 mg of Fingolimod) per capsule.
  • the powder comprises mannitol as a filler and small amount of magnesium stearate as lubricant.
  • US Publication No. 20100040678A1 provides the fast disintegrating solid compositions comprising fingolimod hydrochloride, an alkaline earth metal silicate and a disintegrating agent, which can be easily swallowed e.g. by children or elderly patients.
  • the invention provides dosage forms, which disintegrate rapidly in the mouth and do not depend on the presence of taste masking agent or on presence of water for washing down the dosage forms. It also provides compositions comprising fingolimod, wherein the composition is coated by a mixture comprising one or more polymer resins and one or more metal oxides.
  • US Patent No. 8,324,283 discloses a solid pharmaceutical composition suitable for oral administration comprising fingolimod and a sugar alcohol.
  • the sugar alcohol may act as a diluent, carrier, filler or bulking agent and may suitably be mannitol, maltitol, inositol, xylitol and/or lactitol.
  • US '283 patent teaches that these compositions provide a convenient means of systemic administration of fingolimod, do not suffer from the disadvantages of liquid formulations for injection or oral use, and have good physicochemical and storage properties and in particular, the composition of the invention.
  • compositions of the invention may have high level of uniformity in the distribution of fingolimod hydrochloride throughout the composition, as well as high stability.
  • the composition disclosed may be in a form of a powder, granule, pellet or a tablet.
  • fingolimod hydrochloride is mixed with mannitol and lubricant and, optionally with a binder such as hydroxypropylcellulose or hydroxypropylmethylcellulose, milled and/or granulated.
  • the oral solid dosage forms disclosed in this invention are tablets and capsules.
  • US Publication No. 20130095177 discloses a method of preparing an oral dosage form resulting from the combination of fingolimod and excipients with a particle size of less than 250 ⁇ and greater than 0.6 ⁇ .
  • PCT Publication No. WO2013019872A1 discloses a process for preparing pharmaceutical composition comprising fingolimod in a solid dosage form such as capsules.
  • PCT Publication No. WO2013091704A1 covers a pharmaceutical composition comprising fmgolimod or pharmaceutically acceptable salt or ester thereof, calcium lactate and optionally a lubricant.
  • the oral solid dosage forms disclosed in this invention are tablets and capsules.
  • PCT Publication No. WO20141 11955A1 discloses a pharmaceutical composition comprising fingolimod and weak acid cation exchange resin in the form of ion-exchange complex and pharmaceutically acceptable excipients.
  • the oral dosage forms disclosed in this invention are tablets and capsules.
  • US '918 patent discloses the stable pharmaceutical compositions of fingolimod in free form and one or more excipients:; fillers selected from the group consisting of lactose monohydrate, lactose anhydrous, maize starch, sucrose, microcrystalline cellulose, citric acid and sodium hydrogen carbonate; one or more binders selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylcellulose; one or more disintegrants selected from the group consisting of maize starch, eroscarmellose sodium, sodium carboxymethyl starch, and starch pregelatinized; one or more lubricants selected from the group consisting of hydrogenated castor oil and magnesium stearate; a flow regulator that is colloidal silicone dioxide; and one or more matrix formers selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylcellulose, starch and povidone.
  • the oral solid dosage forms disclosed in this invention are soluble tablets, capsules and sachets.
  • fingolimod is available in the oral conventional dosage forms of tablets, disintegrating tablets, capsules and sachets.
  • Preparing the conventional dosage forms as disclosed in the prior art has many disadvantages including that a large proportion of adjuvants must be added to obtain the dosage form and a larger medication form requires additional storage space.
  • many people, estimated to be as much as 28% of the population have difficulty in swallowing conventional dosage forms.
  • As an alternative to conventional dosage forms disclosed in the prior art there exists a need to develop orally administrable, disintegrating film dosage forms comprising fingolimod.
  • fingolimod due to its reactive amino propane- 1,3-diol group is not amenable to prepare a stable oral formulation. Only a limited amount of suitable pharmaceutical excipients, particularly fillers have been accordingly found. Thus, administration of fingolimod in an alternate and/or improved orally disintegrating film dosage form will be beneficial with its stable and good handling properties.
  • the present invention relates to an orally administrable disintegrating film dosage form comprising fingolimod, which exhibits improved stability upon long term storage and has advantages in handling.
  • the present invention relates to an orally administrable disintegrating film dosage form comprising fingolimod and one or more excipients.
  • the present invention provides an orally administrable, disintegrating film dosage form comprising fingolimod and one or more film forming polymers
  • the present invention provides an orally administrable, disintegrating film dosage form comprising fingolimod, one or more film forming polymers, surfactants and plasticizers.
  • fingolimod means the hydrochloride salt form of fingolimod.
  • the present invention provides an orally administrable disintegrating film dosage form comprising
  • Film forming polymer comprising at least one water soluble polysaccharide, at least one cellulosic polymer or cellulosic derivative polymer, at least one synthetic polymer, and/or combinations thereof.
  • the present invention provides an orally administrable, disintegrating film dosage form comprising
  • Film forming polymer comprising at least one water soluble polysaccharide, at least one cellulosic polymer or cellulosic derivative polymer, at least one synthetic polymer, and/or combinations thereof.
  • the invention relates to an orally administrable, disintegrating film dosage form comprising fingolimod or pharmaceutically acceptable salts thereof and one or more film forming polymers, for use in treatment of patients with relapsing forms of multiple sclerosis (MS).
  • MS multiple sclerosis
  • the present invention provides an orally administrable, disintegrating film dosage form comprising fingolimod or pharmaceutically acceptable salts or solvates thereof.
  • fingolimod refers to fingolimod, pharmaceutically acceptable salts, hydrates, solvates, polymorphs, complexes, and pro-drugs thereof.
  • fingolimod further includes a moiety which yields the fingolimod active component.
  • fingolimod is the hydrochloride salt form of fingolimod.
  • complex is intended to include any construct including fingolimod and a ligand to which it may be associated by any association, including by ionic bond, by covalent bond, by inclusion, or by any other methods of forming a complex desired.
  • fingolimod film/strip dosage form of the present invention that contains about 0.5mg of fingolimod.
  • disintegrate includes dissolving, dispersing or otherwise breaking apart for release of the drug particles and other components contained therein, such that they may be swallowed and/or absorbed into the body, including absorption into the oral cavity and/or the gastro intestinal tract.
  • film includes delivery systems of any thickness, including films, sheets, strips, discs, wafers and the like, in any shape including rectangular, square, or other desired shape.
  • the film may be in the form of a continuous roll of film or may be sized to a desired length and width.
  • the films described herein may be any desired thickness and size suitable for the intended use.
  • a film of the present invention may be sized such that it may be placed into the oral cavity of the user.
  • some films may have relative thickness of about ⁇ to 600 ⁇ , while the others may have a somewhat higher thickness of about 600 ⁇ to ⁇ .
  • the term "film” includes single-layer composition as well as multi-layer compositions, such as laminated films, coatings on the films and the like.
  • the composition in its dried film form maintains a uniform distribution of components.
  • the term "disintegrating film dosage form” refers to a dosage form in the form of a sheet or film that can be administered orally to a subject, preferably a human subject.
  • the disintegrating film dosage form contains fingolimod hydrochloride and one or more pharmaceutically acceptable excipients.
  • the fingolimod hydrochloride in the film dosage form may be dissolved in solution or suspended in the film.
  • the film dosage form Upon placement of the film dosage form in the mouth of a subject, the film dosage form disintegrates, releasing the fingolimod hydrochloride, and making it available for absorption in the oral cavity or gastrointestinal tract.
  • the disintegrating film dosage form rapidly disintegrates, meaning that substantially all of the film dosage form disintegrates in the oral cavity in less than 5 minutes, more preferably in less than 3 minutes, and most preferably in less than 1 minute, after placement in the oral cavity.
  • the fmgolimod hydrochloride used in the present invention may be-of any desirable particle size.
  • the fmgolimod hydrochloride in the film may include smaller sized particles, intermediate sized particles, larger sized particles, and combinations thereof.
  • the fmgolimod hydrochloride may have a particle size of about 0.5 to about 10.0 microns in diameter.
  • the fmgolimod hydrochloride may have a particle size of about 1.0 to about 50.0 microns in diameter.
  • the fmgolimod hydrochloride may have a particle size of about 3.0 to about 200.0 microns in diameter.
  • the present invention provides an orally administrable, disintegrating film dosage form comprising
  • Film forming polymer comprising at least one water soluble polysaccharide, at least one cellulosic polymer or cellulosic derivative polymer, at least one synthetic polymer, and a combination thereof.
  • the disintegrating film dosage form includes one or more film-forming polymers.
  • the film- forming polymer may be a water soluble polymer, a water insoluble polymer, or a combination of one or more water soluble polymers and/or water insoluble polymers.
  • water soluble polymer and variants thereof refer to a polymer that is at least partially soluble in water, and desirably fully or predominantly soluble in water, or absorbs water. Polymers that absorb water are often also referred to as being water swellable polymers, and this term is synonymous for the purposes of the present invention.
  • the materials useful with the present invention may be water soluble at room temperature and other temperatures, such as temperatures exceeding room temperature. Moreover, the materials may be water soluble at pressures less than atmospheric pressure. Desirably, the water soluble polymers have at least 20 percent by weight water uptake. Water soluble polymers having a 25 or greater percent by weight water uptake are also useful.
  • Films or dosage forms of the present invention formed from such water soluble polymers are desirably sufficiently water soluble to be disintegratable upon contact with oral fluids.
  • water soluble polymers include, but are not limited to water-soluble polysaccharides, cellulose polymers or cellulosic derivative polymers, and water-soluble synthetic polymers.
  • Water soluble polysaccharides include, maltodextrin, sodium alginate, carrageenans, guar gum, acacia gum, agar, xanthan gum, gellan gum, arable gum and related gums (gum ghatti, gum karaya, gum tragacanth), and pectin.
  • the most preferred water soluble polysaccharide is maltodextrin.
  • the disintegrating film dosage form includes one or more water soluble polysaccharides.
  • cellulosic polymers and cellulosic derivative polymers include, but are not limited to alkyl celluloses, hydroxyalkylcelluloses and hydroxyalkylcelluloses such as methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethyl- methylcellulose, hydroxypropylmethylcellulose, hydroxybutylmethylcellulose, cellulose esters and hydroxyalkylcellulose esters such as cellulose acetate phthalate; carboxyalkylcelluloses, carboxyalkylcellulose esters such as carboxymethylcellulose and their alkali metal salts.
  • the cellulose polymer and cellulosic derivative polymers include, but are not limited to, methylcellulose, ethylcellulose, hydroxypropyl ethylcellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, and combinations thereof.
  • the most preferred cellulose polymer is hydroxypropyl methylcellulose.
  • the disintegrating film dosage form includes one or more cellulose polymers or cellulosic derivative polymers
  • Synthetic polymers include, but are not limited to polyacrylic acids and polyacrylic acid esters, polymethacrylic acids and polymethacrylic acid esters, polyalkylene oxides, such as polyethylene oxide, polyvinylacetates, polyvinylalcohols, polyvinylacetatephthalates (PVAP), polyvinylpyrrolidone (PVP), polyvinyl acetate copolymers, and poly(crotonic acid derivatives; also suitable are phthalated gelatin, gelatin succinate, crosslinked gelatin, shellac, water soluble chemical derivatives of starch, cationic modified acrylates and methacrylates possessing, for example, a tertiary or quaternary amino group, such as the diethylaminoethyl group, which may be quarternized if desired.
  • the most preferred synthetic polymer is polyethylene oxide.
  • the disintegrating film is polyethylene oxide
  • the disintegrating film dosage form includes one or more film- forming polymers, preferably one or more cellulose polymers or cellulosic derivative polymers.
  • the total amount of the one or more film-forming polymers ranges from about 5% to about 95%, preferably about 10% to about 85%, and more preferably about 20% to about 75%, by weight of the dosage form.
  • the dosage form includes two or more film-forming polymers, preferably at least one water soluble polysaccharides, at least one cellulose polymer or cellulosic derivative polymer and at least one synthetic polymer.
  • water soluble polysaccharide desirably ranges from about 0% to 50% w/w of the total weight of the water soluble polymer component of the film dosage form, preferably from about 10% to 45% w/w of the total weight of the water soluble polymer component and more preferably from about 20% to 40% w/w of the total weight of water soluble polymer component of the film dosage form.
  • cellulosic polymers or cellulosic derivative polymer desirably ranges from about 0% to 80% w/w of the total weight of the water soluble polymer component of the film dosage form, preferably from about 10% to 70% w/w of the total weight of the water soluble polymer component and more preferably from about 15% to 60% w/w of the total weight of water soluble polymer component of the film dosage form.
  • synthetic polymer desirably ranges from about 0% to 20% w/w of the total weight of the water soluble polymer component of the film dosage form, preferably from about 2% to 15% w/w of the total weight of the water soluble polymer component and more preferably from about 5% to 10% w/w of the total weight of water soluble polymer component of the film dosage form.
  • the present invention provides an orally administrable, disintegrating film dosage form comprising
  • Film forming polymer comprising at least one water soluble polysaccharide, at least one cellulosic polymer or cellulosic derivative polymer, at least one synthetic polymer, and a combination thereof.
  • the disintegrating film dosage form of the invention also may include a variety of other pharmaceutically acceptable excipients.
  • these may include, without limitation, surfactants; plasticizers which assist in compatibilizing the components within the mixture; polyalcohols; anti-foaming agents, such as silicone-containing compounds, which promote a smoother film surface by releasing gases, such as oxygen, from the film; and thermo-setting gels such as pectin, carrageenan, and gelatin, which help in maintaining the dispersion of components.
  • the surface active agents i.e. surfactants, present in this invention include, but are not limited to, cetyl alcohol, sodium lauryl sulfate, and the commercially available polysorbates for example the SpanTM and TweenTM (polysorbate-80). Ethoxylated oils, including ethoxylated castor oils, and commercially available ones such as Cremophor® are also useful. TweenTM or combinations of surface active agents may be used to achieve the desired hydrophilic-lipophilic balance ("HLB").
  • HLB hydrophilic-lipophilic balance
  • surface active agents desirably range from about 0% to 10% w/w of the total weight of the film dosage form.
  • plasticizer significantly improves the strip properties by reducing the glass transition temperature of the polymer.
  • plasticizers which include polyalkylene oxides, such as polyethylene glycols, polypropylene glycols, polyethylene-propylene glycols, organic plasticizers with low molecular weights, such as glycerol, glycerol monoacetate, diacetate or triacetate, triacetin, polysorbate, cetyl alcohol, propylene glycol, sorbitol, sodium diethylsulfosuccinate, triethyl citrate, tributyl citrate, and the like, which may be added in concentrations ranging from about 0 % to about 30% w/w of the total weight of the film dosage form.
  • co-polymers which contribute to the ease of formation and general quality of the films.
  • co-polymers include starches, pregelatinized starches, gelatin, polyvinylpyrrolidone, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamides, polyvinyloxoazolidone, and polyvinylalcohols.
  • the present invention further includes incorporation of a taste masking agent wherein the taste masking agent is carboxylic acid ion exchange resin comprising methacrylic acid cross-linked with divinyl benzene or polymers or cellulosics such as ethyl cellulose.
  • the taste masking agent as per the present invention is Methacrylic acid polymer with divinylbenzene, potassium salt (Polacrilin Potassium).
  • the present invention optionally further comprises pharmaceutical additives such as fillers and/or disintegrants.
  • the amount of filler may range from about 1 to 20% w/w of the total dosage form.
  • the filler may include at least one selected from group consisting of mannitoi, microcrystaiiine DCiufose, lactose.
  • the amount of the disintegrant may range from about 1 to 10% w/w of the total dosage form. Examples of disintegrants include crospovidone, crosscarmellose sodium, sodium starch glycolate and pre-gelatinized starch.
  • Buffering agents or pH adjusting agents may also be used, such as calcium carbonate, sodium bicarbonate, citric acid, tartaric acid, succinic acid, maleic acid, and fumaric acid.
  • Antioxidants and preservatives may also be added to the film.
  • antioxidants and preservatives include, but are not limited to parabens, such as methyl paraben, ethyl paraben, propyl paraben, and butyl paraben, benzoic acid, sodium benzoate, sorbic acid, sodium sorbate, cetrimide, benzalkonium chlorise, cetylpyridium chloride, benzaethonium chloride, phenylmercuric nitrate, benzyl alcohol, phenylethyl alcohol, bronabol, chlorbutanol, chlorhexidine, butylated hydroxyanisole, butylated hydroxytoluene, tert-butyl hydroquinone, and 4-hydroxymethyl-2,6,-di-ter-butylphenol.
  • parabens such as methyl paraben, ethyl paraben, propyl paraben, and butyl paraben
  • benzoic acid sodium benzoate
  • sorbic acid sodium sorbate
  • the present investigation may include incorporation of color additives of food, drug and cosmetic usage colors (FD&C), drug and cosmetic colors (D&C), or external drug and cosmetic colors. These colors are dyes, their corresponding lakes, and certain natural and derived colorants. Lakes are dyes absorbed on aluminum hydroxide. Other examples of coloring agents include known azo dyes, organic or inorganic pigments, or coloring agents of natural origin. FD&C colors are preferred and most preferred is FD&C Blue No.l .
  • Flavors may be chosen from natural and synthetic flavoring liquids.
  • An illustrative list of such agents includes volatile oils, synthetic flavor oils, flavoring aromatics, oils, liquids, oleoresins or extracts derived from plants, leaves, flowers, fruits, stems and combinations thereof.
  • a non- limiting representative list of examples includes mint oils (peppermint flavor), cocoa, and citrus oils such as lemon, orange, grape, lime and grapefruit and fruit essences including apple, pear, peach, grape, strawberry, raspberry, cherry, plum, pineapple, apricot or other fruit flavors.
  • aldehydes and esters such as benzaldehyde (cherry, almond), citral i.e., alphacitral (lemon, lime), neral, i.e., beta-citral (lemon, lime), decanal (orange, lemon), aldehyde C-8 (citrus fruits), aldehyde C-9 (citrus fruits), aldehyde C-12 (citrus fruits), tolyl aldehyde (cherry, almond), 2,6-dimethyloctanol (green fruit), and 2-dodecenal (citrus, mandarin), combinations thereof and the like.
  • aldehydes and esters such as benzaldehyde (cherry, almond), citral i.e., alphacitral (lemon, lime), neral, i.e., beta-citral (lemon, lime), decanal (orange, lemon), aldehyde C-8 (citrus fruits), aldeh
  • the sweeteners may be chosen from the following non-limiting list: glucose (corn syrup), dextrose, invert sugar, fructose, and combinations thereof; saccharin and its various salts such as the sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds. glycyrrhizin; Stevia Rebaudiana (Stevioside); chloro derivatives of sucrose such as sucralose; sugar alcohols such as sorbitol, mannitol, xylitol, and erythritol.
  • hydrogenated starch hydrolysates and the synthetic sweetener 3,6-dihydro-6-rnethyl-l-l-l,2,3-o- xathiazin-4-one-2,2-dioxide particularly the potassium salt (acesulfame-K), ammoniated glycyrrhizin and monoammonium glycyrrhizinate, and sodium and calcium salts thereof, and natural intensive sweeteners.
  • Other sweeteners may also be used.
  • step (a) solution Adding at least one surfactant into step (a) solution.
  • step (b) solution Adding at least one coloring additives into step (b) solution.
  • step (c) solution Adding at least one sweetener to into step (c) solution.
  • step (d) Adding at least water soluble polysaccharide into step (d).
  • step (e) Adding at least one synthetic polymer into step (e)
  • step (f) Adding at least one cellulosic polymers or cellulosic derivative polymer into step (f) h) Adding at least one plasticizer into step (g)
  • step (h) Adding at least one flavor into step (h)
  • the present invention also provides for methods of using the disintegrating film dosage forms.
  • the disintegrating film dosage form is placed in the oral cavity of the subject, such as on the tongue, and allowed to disintegrate completely.
  • the disintegrating film dosage form may be administered to a subject in a fed state or a fasted state.
  • the disintegrating film dosage form may also be administered with or without the administration of water.
  • more than one disintegrating film may be administered sequentially. When more than one disintegrating film dosage form is administered sequentially, preferably the subject places the disintegrating film dosage form in the oral cavity and allows the dosage form to completely disintegrate before administration of the next dosage form.
  • the disintegrating film dosage form of fingolimod hydrochloride is used for treatment of patients with relapsing forms of multiple sclerosis (MS).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des formes posologiques de film à désintégration, administrables par voie orale, comprenant du fingolimod ou des sels ou solvates pharmaceutiquement acceptables correspondants .
PCT/IB2016/054102 2015-07-16 2016-07-08 Forme posologique de film administrable par voie orale contenant du fingolimod WO2017009754A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3654/CHE/2015 2015-07-16
IN3654CH2015 2015-07-16

Publications (1)

Publication Number Publication Date
WO2017009754A1 true WO2017009754A1 (fr) 2017-01-19

Family

ID=57757745

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/054102 WO2017009754A1 (fr) 2015-07-16 2016-07-08 Forme posologique de film administrable par voie orale contenant du fingolimod

Country Status (1)

Country Link
WO (1) WO2017009754A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150231065A1 (en) * 2012-09-28 2015-08-20 Pharmafilm S.R.L. Orodispersible films having quick dissolution times for therapeutic and food use
US10555902B2 (en) 2015-01-20 2020-02-11 Handa Pharmaceuticals Llc Stable fingolimod dosage forms

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013098402A1 (fr) * 2011-12-30 2013-07-04 Deva Holding Anonim Sirketi Combinaison pharmaceutique de fingolimod et de nabiximols
US20150141520A1 (en) * 2013-11-18 2015-05-21 Chandrasekhar Kandi Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013098402A1 (fr) * 2011-12-30 2013-07-04 Deva Holding Anonim Sirketi Combinaison pharmaceutique de fingolimod et de nabiximols
US20150141520A1 (en) * 2013-11-18 2015-05-21 Chandrasekhar Kandi Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150231065A1 (en) * 2012-09-28 2015-08-20 Pharmafilm S.R.L. Orodispersible films having quick dissolution times for therapeutic and food use
US11123287B2 (en) * 2012-09-28 2021-09-21 Pharmafilm S.R.L. Orodispersible films having quick dissolution times for therapeutic and food use
US10555902B2 (en) 2015-01-20 2020-02-11 Handa Pharmaceuticals Llc Stable fingolimod dosage forms
US10925829B2 (en) 2015-01-20 2021-02-23 Handa Neuroscience, Llc Stable solid fingolimod dosage forms

Similar Documents

Publication Publication Date Title
JP6545839B2 (ja) 口腔内崩壊錠及びその製造方法
BRPI0714514B1 (pt) Grânulo compreendendo núcleo revestido por oxicodona, bem como comprimido para desintegração oral e seu processo de fabricação
BG64368B1 (bg) Фармацевтични състави на итраконазол
US20110160264A1 (en) Orally administrable film dosage forms containing ondansetron
KR20080013847A (ko) 활성 약제학적 성분의 안정화 조성물 및 방법
US11279682B2 (en) Vortioxetine pyroglutamate
FI117373B (fi) Parasetamolia ja domperidonia sisältävä kalvopäällysteinen tabletti
JP5974469B2 (ja) 錠剤の製造方法
JP5208729B2 (ja) 徐放性錠剤の製造方法
WO2017009754A1 (fr) Forme posologique de film administrable par voie orale contenant du fingolimod
US20230047314A1 (en) Oral film formulation for modulating absorption profile
US20110060008A1 (en) Pharmaceutical composition containing acetylcholine esterase inhibitor and method for the preparation thereof
CA2853117A1 (fr) Composition pharmaceutique sublinguale contenant un antihistaminique et procede de preparation associe
WO2010084637A1 (fr) Comprimé prévu pour une administration orale présentant une excellente capacité de délitement et de dissolution
JP2010001242A (ja) レバミピド固形製剤及びその製造方法
WO2019230937A1 (fr) Forme galénique solide pour la voie orale possédant d'excellentes propriétés de dissolution
BRPI0612990A2 (pt) formulação de liberação prolongada de princìpios ativos de medicamentos
WO2003075919A1 (fr) Comprime contenant du chlorhydrate de pilsicainide (voie seche)
JP2020083884A (ja) イブプロフェン含有経口用医薬製剤
WO2013095317A2 (fr) Formulations pharmaceutiques de flurbiprofène et glucosamine
US20230201123A1 (en) Pharmaceutical composition
TW202315862A (zh) 布瓦西坦藥物組合物、其製備方法及應用
JP2021102610A (ja) 医薬組成物
JP2024004706A (ja) 医薬組成物及び医薬製剤
JP2021075530A (ja) 医薬組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16823959

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16823959

Country of ref document: EP

Kind code of ref document: A1